Clinical Trials
48 trialsA Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Institutes of Health Clinical Center (CC)
TTV ccRCC
Regina Elena Cancer Institute
BASECAMP-1
A2 Biotherapeutics Inc.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
DP-04
AstraZeneca
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Institutes of Health Clinical Center (CC)
PEP-C
Centre Hospitalier Universitaire de Saint Etienne
RCCETT
Peking University Third Hospital
PP-RECURK
Gødstrup Hospital
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Tel-Aviv Sourasky Medical Center
TARGET-RCC
IRCCS San Raffaele
ELEPHAS-04
Mayo Clinic
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
COSTAR
Peking University First Hospital
PET/MR for Characterization of Renal Masses (RMs)
University of Texas Southwestern Medical Center
Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy
Jinling Hospital, China
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Jinling Hospital, China
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Jinling Hospital, China
AURICRE
University of Yamanashi
International Multicentric Study ARON-1
Hospital of Macerata
PRCC
AstraZeneca
CARAT
iOMEDICO AG
ST-ICI02
University of Erlangen-Nürnberg Medical School
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
Peking University First Hospital
ORACLE
Guardant Health, Inc.
Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PRO-RCC
PROspective Renal Cancer Cohort Foundation
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
First Affiliated Hospital of Chongqing Medical University
SDM-RCC
St. Antonius Hospital
Serpentine
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma
The Affiliated Hospital of Qingdao University
The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function After Partial Nephrectomy: A Prospective Study
The First Affiliated Hospital with Nanjing Medical University
Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
Fondazione IRCCS Policlinico San Matteo di Pavia
BIOPSy
Loyola University
Optimising Renal Tumour Management Through Artificial Intelligence Modules
The First Affiliated Hospital with Nanjing Medical University
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics, Inc.
CABOGEN
Gruppo Oncologico Italiano di Ricerca Clinica
Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms
IRCCS San Raffaele
EASE
Azienda Ospedaliero Universitaria Maggiore della Carita
SoMuKT
IRCCS San Raffaele
BRC
Biorek S.R.L.
Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion
Peking University Third Hospital
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Yonsei University
PARADIGM
VastBiome
Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma
Qianfoshan Hospital
Urine Omics Predicting IO Therapy Responses in mRCC Patients
National Taiwan University Hospital
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Yonsei University